EFElena Ferrer

Elena Ferrer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Ferrer has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Podzamczer

    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, 08907 Barcelona, Spain

    2 shared publications
  • Jordi Curto

    Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain

    2 shared publications
  • Anna Esteve

    Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agencia de Salut Publica de Catalunya (ASPC), Generalitat de Catalunya, 08916 Badalona, Spain CIBER Epidemiología y Salud Pública (CIBERESP), 08036 Barcelona, Spain Fundació Institut d'Investigació Germans Trias i Pujol (IGTP), 08916 Badalona, Spain Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine, Universitat Autónoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallés), Spain

    1 shared publication
  • Cristina Tural

    Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, 2a planta Maternal, Ctra. de Canyet s/n, 08916 Badalona, Barcelona, Spain

    1 shared publication
  • Esteban Martínez

    Service of Infectious Diseases, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    1 shared publication
  • Esteban Ribera

    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Barcelona, España

    1 shared publication

Latest Publications

  • Open Access

    Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

    by Elena Ferrer, Jordi Curto, Anna Esteve, Jose M. Miro, Cristina Tural, Javier Murillas, Ferran Segura, Pilar Barrufet, Jordi Casabona, Daniel Podzamczer

    The aim of this study was to analyse factors associated with progression to AIDS/death in severely immunosuppressed HIV-infected patients receiving ART. This study included naive patients from the PISCIS Cohort with CD4 18 years followed at 14 participating hospitals in Catalonia and the Balearic Islands (Spain). Clinical and laboratory parameters were assessed every 3–4 months during follow-up. Cox regression models were used to assess the effect of CD4 and viral load on the risk of progression to AIDS/death, adjusting for baseline variables and confounders. 2295 patients were included and, after 5 years, 69.9% reached CD4 ≥200 cells/mm3, 64.4% had an undetectable viral load and 482 (21%) progressed to AIDS/death. The lowest rate of disease progression was found in patients who reached both immunological and viral responses during follow-up, regardless of their baseline situation (1.9% in baseline CD4 >100 cells/mm3 and viral load 5 log copies/mL). Achieving a CD4 count ≥200 cells/mm3 was the main predictor of decreased progression to AIDS/death. In those not reaching this CD4 threshold, virological response reduced disease progression by half. Even in the worse baseline scenario of CD4 ≤100 cells/mm3 and high baseline viral loads, positive virological and immunological responses were associated with dramatic decreases in progression.


  • Open Access

    Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults

    by Elena Ferrer, Luis del Rio, Esteban Martínez, Jordi Curto, Pere Domingo, Esteban Ribera, Eugenia Negredo, Joaquim Rosales, Maria Saumoy, Jordi Ordóñez, et al.

    Changes in body fat distribution in virologically suppressed HIV-infected patients switching from lopinavir/ritonavir (LPV/r) to atazanavir/ritonavir (ATV/r) were assessed. A prospective comparative study was conducted of 37 patients receiving LPV/r regimens switching to ATV/r with 46 patients continuing with LPV/r. Body composition was assessed with whole-body dual-energy x-ray absorptiometry (DXA). Abdominal CT scans were also performed in a subset of patients. Groups were comparable in baseline demographic, clinical, and anthropometric characteristics. After 12 months, peripheral fat did not change significantly, but an increase in trunk fat was observed only in the ATV/r group (0.87 kg, p = 0.021). The percentage of patients with an increase ≥20% in total fat was 37.8% and 15.2% in the ATV/r and LPV/r groups, respectively (p = 0.018). In the ATV/r group, the increase in trunk fat (9.4%) was significantly higher than in peripheral fat (3.7%) (p = 0.007), leading to a significant increase in fat mass ratio (3.76%, p = 0.028), whereas no significant differences were found among LPV/r patients. CT scans showed that abdominal fat increase corresponded to both visceral (28%, p = 0.008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral.